Pharmacological profile of progestins

Henzl MR, Edwards JA. Pharmacology of progestins: 17α-hydroxyprogesterone derivatives and progestins of the first and second generation. In: Sitruk-Ware R, Mishell Jr DR, editors. Progestins and antiprogestins in clinical practice. New York: Marcel Dekker; 2000. p. 101–32.

Sitruk-Ware, 2002, Progestogens in HRT: new molecules, Menopause, 9, 6, 10.1097/00042192-200201000-00003

Oettel M, Holz C. Hybrid progestins: the example of dienogest. In: Sitruk-Ware R, Mishell Jr DR, editors. Progestins and anti-progestins in clinical practice. New York: Marcel Dekker, 2000. p. 163–78.

Oelkers, 1995, Effects of the new oral contraceptive containing an anti-mineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism, J Clin Endocrinol Metab, 80, 1816, 10.1210/jc.80.6.1816

Tuba, 2000, Synthesis and biological activity of a new progestogen, 16-methylene-17a-hydroxy-18-methyl-10-norpregn-4ene-3, 20-dione acetate, Steroids, 65, 266, 10.1016/S0039-128X(99)00109-9

Paris, 1983, The pharmacological profile of TX 066 (17a-acetoxy-6methyl-19-nor-4, 6-pregna-diene-3, 20-dione) a new oral progestative, Drug Res, 33, 710

Kumar, 2000, Nestorone®: a progestin with a unique pharmacological profile, Steroids, 65, 629, 10.1016/S0039-128X(00)00119-7

Philibert, 1999, The pharmacological profile of a novel norpregnane progestin (trimegestone), Gynecol Endocrinol, 13, 316, 10.3109/09513599909167574

Bullock, 1977, Androgenic, synadrogenic and anti-androgenic actions of progestins, Ann NY Acad Sci., 286, 321, 10.1111/j.1749-6632.1977.tb29427.x

Duc, 1995, Anti-androgenic properties of nomegestrol acetate, Arzneim Forsch/Drug Res, 45, 70

Hellman, 1976, The effect of medroxyprogesterone acetate on the pituitary-adrenal axis, J Clin Endocrinol Metab, 42, 912, 10.1210/jcem-42-5-912

Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51:188–215.

Dusterberg, 1981, Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys, Contraception, 24, 673, 10.1016/0010-7824(81)90018-4

Fuhrmann, 1996, The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and anti-androgenic potential, Contraception, 54, 243, 10.1016/S0010-7824(96)00195-3

Pollow, 1991, Dihydrospirorenone (ZK30595), a new progestogen with anti-mineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin–aldosterone system in normal women, J Clin Endocrinol Metab, 73, 837, 10.1210/jcem-73-4-837

Ezan, 1993, Enzyme immunoassay for nomegestrol acetate in human plasma, J Steroid Biochem Mol Biol, 46, 507, 10.1016/0960-0760(93)90105-6

Noé, 1993, Pharmacokinetics and bioavilability of ST1435 administered by different routes, Contraception, 48, 548, 10.1016/0010-7824(93)90117-P

Oelkers, 1991, Dihydrospirenone, a new progestogen with anti-mineralocorticoid activity: effects on ovulation, electrolyte excretion, and the rennin–aldosterone system in normal women, J Clin Endocrinol Metab, 73, 837, 10.1210/jcem-73-4-837

Foidart, 2000, A comparative investigation of contraceptive reliability, Eur J Contracept Reprod Health Care, 5, 124, 10.1080/13625180008500387

Huber, 2000, Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone, Eur J Contracept Reprod Health Care, 5, 25, 10.1080/13625180008500375

Wiegratz, 2002, Effect of dienogest-containing oral contraceptives on lipid metabolism, Contraception, 65, 223, 10.1016/S0010-7824(01)00310-9

Foster, 1998, Dienogest, Drugs, 56, 825, 10.2165/00003495-199856050-00007

Williams, 1994, Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys, J Am Coll Cardiol, 24, 1757, 10.1016/0735-1097(94)90184-8

Williams, 1998, Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in non human primates, Am J Obstet Gynecol, 179, 1288, 10.1016/S0002-9378(98)70149-8

Adams, 1990, Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone, Arteriosclerosis, 10, 1051, 10.1161/01.ATV.10.6.1051

Kemmeren JM, Algra A, Meijers JCM, Bouma BN, Grobbee DE. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of factor V leaden mutation. Thromb Haemost 2002;87:199–205.

Lidegaard, 2002, Oral contraceptives and venous thromboembolism: a five-year national case–control study, Contraception, 65, 187, 10.1016/S0010-7824(01)00307-9

Odlind V, Milsom I, Persson, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002;81:482–90.

Mashchak, 1982, Comparison of pharmacodynamic properties of various estrogen formulations, Am J Obstet Gynecol, 144, 511, 10.1016/0002-9378(82)90218-6

Writing group for the Women’s Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33.